Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that its proprietary PDAOAI drug discovery and development platform will be featured during the Product & Engineering keynote at Qdrant Vector Space Day 2026 in San Francisco on June 11. Company executives will join Qdrant leadership to discuss how PDAOAI, operating on Qdrant infrastructure, has helped accelerate the development of two drug candidates from concept to investigational new drug filings in less than two years, significantly reducing the time and cost traditionally associated with pharmaceutical development.
The presentation will highlight several innovations underpinning the platform, including a proprietary 'manifold folding' technique designed to improve semantic retrieval accuracy and reduce large language model hallucinations, as well as the indexing of approximately 28 million PubMed biomedical abstracts on Qdrant Cloud. Oncotelic said the platform leverages advanced vector search technologies to support large-scale biomedical research and accelerate oncology drug discovery efforts.
This demonstration at a major industry event underscores the growing importance of AI in pharmaceutical development. By integrating PDAOAI with Qdrant's vector search capabilities, Oncotelic aims to transform how drug candidates are identified and advanced, potentially bringing new treatments to patients faster and at lower cost. The company's achievements in reducing development timelines from years to under two years highlight a significant shift in the efficiency of drug discovery processes.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy. The company's PDAOAI platform supports research, biomarker discovery, and regulatory processes through advanced data analysis. Additionally, Oncotelic benefits from a robust portfolio of inventions by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents.
The Qdrant Vector Space Day 2026 event provides a platform for Oncotelic to showcase its technological advancements to a broader audience of industry professionals and potential partners. For more information about Oncotelic, visit the company's newsroom at https://ibn.fm/OTLC.
